StreetAlpha.app
Home › Stocks › TTRX

Turn Therapeutics Inc. (TTRX)

$8.55
▲ +0.00%
LAST CLOSE · NOV 17

Turn Therapeutics develops topical drug candidates for skin conditions and licenses wound care medical devices to partners. It last closed at $8.55 on Nov 17, up 0.00% on the day. The average 12-month price target from 2 analysts is $17.00 (+98.8% from the last close), with a high of $24.00 and a low of $10.00.

AI Auto Pilots
Is TTRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$12.8M
EPS (diluted)
−$0.43
Valuation
Market cap
$261.4M
30.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$9.4M
At Sep 30
Debt
$7.3M
At Sep 30
Shareholder equity
$5.7M
Shares outstanding
30.6M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: −$1.8M−$1.8MFY2024FY2025: −$3.2M−$3.2MFY2025

From TTRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated TTRX in the past 90 days, not enough for a consensus
Average 12-month target
$17.00
▲ 98.8% upside

Based on 2 analysts who set a price target on TTRX in the past 90 days. The average target is $17.00, with a high of $24.00 and a low of $10.00, compared with the last close of $8.55.

Low $10.00Avg $17.00High $24.00
Blue marker: last close $8.55
Highest target$24.00
Average target$17.00
Lowest target$10.00
Latest rating changes
WBB SecuritiesUpgrade
Oct 23Hold$10
LUCID CAPITAL MARKETSInitiated
Sep 24Buy$24
WBB SecuritiesDowngrade
Sep 14Sell$10
DateFirmActionRatingPrice target
Oct 23WBB SecuritiesUpgradeHold$10
Sep 24LUCID CAPITAL MARKETSInitiatedBuy$24
Sep 14WBB SecuritiesDowngradeSell$10
Loading…

Technical Analysis

TTRX · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 16% below its 20 day and 36% below its 50 day average. It is 15% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 36), near oversold. The nearest support is the swing low (Jul 17) at $8.51, and the nearest resistance the Pivot at $8.58.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 12.0%/day
Key levels
$16.4552 week high+92.4%
$11.6150 day average+35.8%
$10.48Swing high (Jul 21)+22.6%
$10.45100 day average+22.2%
$9.9120 day average+15.9%
$9.07Pivot R1+6.1%
$8.58Pivot+0.4%
$8.55Last close
$8.51Swing low (Jul 17)−0.5%
$8.06Pivot S1−5.7%
$7.30200 day average−14.6%
$2.5752 week low−69.9%
Indicators
RSI (14)36.50Weak, oversold below 30Neutral
MACD-0.59Below its signal lineBearish
Stochastic19.6Near the bottom of its rangeOversold
ADX (14)23.2Weak trend
Williams %R-85.7Oversold below −80, overbought above −20Oversold
CCI (20)-174.3Oversold below −100, overbought above 100Oversold
Rate of change−10.1%Change over 10 sessionsBearish
ATR (14)$1.02Typical daily range, 12.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for TTRX

What happened before

See how TTRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in TTRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

TTRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲27 buying vs 7 selling
  • ▲Held by funds +3.7 pts
  • ▲Funds holding +14
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4329+48.3%
In funds' top 1000–
Held by funds7.6%3.9%+3.7 pts
New / increased16 / 1110 / 4+92.9%
Reduced / sold out4 / 32 / 2+75.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TTRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TTRX is in one of them and how their past TTRX trades turned out.

TTRX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TTRX in an article yet. Here's the latest on the wider market.

About Turn Therapeutics

Turn Therapeutics is a drug development company based in Westlake Village, California. It is developing GX-03, a topical treatment for inflammatory skin conditions, with programs aimed at moderate to severe eczema and nail fungus, known as onychomycosis. The company also licenses wound care and dermatitis medical devices to commercial partners, including Medline. Its drug candidate uses polyhexanide, a polymer with a long history of use in wound care.

Headquarters
Westlake Village, CA